Embryonic Stem Cell Research Oversight Committees
The National Academies called for the establishment of Embryonic Stem Cell Research Oversight (ESCRO) Committees in its 2005 "Guidelines for Human Embryonic Stem Cell Research" to manage the ethical and legal concerns in human embryonic stem cell research. Because of the complexity and novelty of many of the issues involved in that research, the Guidelines committee believes that all research institutions engaged in human embryonic stem cell research should create and maintain these committees at the local level.
Embryonic stem cell
Embryonic stem cells (ES cells or ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. Isolating the embryoblast, or inner cell mass (ICM) results in destruction of the blastocyst, a process which raises ethical issues, including whether or not embryos at the pre-implantation stage should have the same moral considerations as embryos in the post-implantation stage of development. Researchers are currently focusing heavily on the therapeutic potential of embryonic stem cells, with clinical use being the goal for many labs. Potential uses include the treatment of diabetes and heart disease. The cells are being studied to be used as clinical therapies, models of genetic disorders, and cellular/DNA repair. However, adverse effects in the research and clinical processes such as tumours and unwanted immune responses have also been reported.